Tyra Biosciences, Inc. (TYRA) Dividend History

Company News

• BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight

  BALVERSA (erdafitinib), a targeted therapy for FGFR-altered urothelial carcinoma, has strong market potential as precision oncology gains emphasis. Its uptake is expected to increase, especially if expanded to earlier treatment lines or additional FGFR-driven tumors.

  GlobeNewswire Inc.

  Featured Companies: JNJ PFE URGN
• Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

  The advanced urothelial carcinoma market is witnessing significant growth, driven by an aging population and the rising prevalence of metastatic cases. Advances in immunotherapy and targeted treatments are transforming the treatment landscape, with over 20 key companies developing new therapies.

  GlobeNewswire Inc.

  Featured Companies: BMY
• Tyra Biosciences hits 52-week high, reaching $21.67 By Investing.com - Investing.com Australia

  Tyra Biosciences, a leading biotechnology company, has reached a new 52-week high of $21.67, reflecting its robust performance and investor confidence. The company has made progress in the development of its therapeutic candidate TYRA-300 for hypochondroplasia, with positive preclinical data presented at a research conference.

  Investing.com
• Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?

  Tyra Biosciences (TYRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  Zacks Investment Research
• Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?

  The consensus price target hints at a 27.3% upside potential for Tyra Biosciences (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  Zacks Investment Research